Expert Interview
Investigating Interim Phase 1 Results of 4D-170 by 4D Molecular Therapeutics for the Treatment of Cystic Fibrosis
Ticker(s): FDMT, VRTXInstitution: University of Cincinnati College of Medicine
- Professor of Clinical Medicine and Director of the Adult Cystic Fibrosis Program within the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Cincinnati
- Manages over 200 adult patients with complex pulmonary conditions, including cystic fibrosis.
- Research interests focus on cystic fibrosis, bronchiectasis, and general pulmonary disease, with an emphasis on clinical trials and improving patient-centered outcomes
What is your current treatment algorithm for patients with cystic fibrosis?
Added By: max_adminHow would 4d-170 fit into your treatment algorithm based on these results?
Added By: max_adminRank your excitement for 4D-170 on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
